[go: up one dir, main page]

MX2022007227A - Compuestos para el tratamiento de la enfermedad de alzheimer. - Google Patents

Compuestos para el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2022007227A
MX2022007227A MX2022007227A MX2022007227A MX2022007227A MX 2022007227 A MX2022007227 A MX 2022007227A MX 2022007227 A MX2022007227 A MX 2022007227A MX 2022007227 A MX2022007227 A MX 2022007227A MX 2022007227 A MX2022007227 A MX 2022007227A
Authority
MX
Mexico
Prior art keywords
hydroxy
alzheimer
disease
treatment
compounds
Prior art date
Application number
MX2022007227A
Other languages
English (en)
Inventor
Der Graaf Adrianus Cornelis Van
Robert Henk Henning
Guido Krenning
Daniël Henri Swart
Veij Mestdagh Christina Françoise De
Pieter Cornelis Vogelaar
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of MX2022007227A publication Critical patent/MX2022007227A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a determinados compuestos de cromanol, quinona o hidroquinona y derivados de estos para el tratamiento de la enfermedad de Alzheimer y/o para mejorar la función de la memoria y/o reducir la carga de placa. Específicamente, la presente invención se refiere a compuestos de cromanol elegidos a partir de (6-hidroxi-2,5,7,8-tetrametilcroman-2il)(piperazin-1-5 il)metanona, clorhidrato de ((S)-6-hidroxi-2,5,7,8-tetrametil-N-(( R)-piperidin-3-il)croman-2-carboxamida y S-(6-hidroxi-2,5,7,8-tetr ametilcro-man-2-il)(4-(2-hidroxietil)piperazin-1-il)metanona y sales farmacéuticamente aceptables de estos.
MX2022007227A 2019-12-11 2020-12-11 Compuestos para el tratamiento de la enfermedad de alzheimer. MX2022007227A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2024431A NL2024431B1 (en) 2019-12-11 2019-12-11 Compounds for treatment of alzheimer’s disease
PCT/NL2020/050782 WO2021118359A1 (en) 2019-12-11 2020-12-11 Compounds for treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2022007227A true MX2022007227A (es) 2022-09-19

Family

ID=69173381

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007227A MX2022007227A (es) 2019-12-11 2020-12-11 Compuestos para el tratamiento de la enfermedad de alzheimer.

Country Status (16)

Country Link
US (1) US20230052152A1 (es)
EP (1) EP4072550A1 (es)
JP (1) JP7695246B2 (es)
KR (1) KR20220119032A (es)
AU (1) AU2020400823A1 (es)
BR (1) BR112022011344A2 (es)
CA (1) CA3164071A1 (es)
CL (1) CL2022001520A1 (es)
GE (1) GEAP202516676A (es)
IL (1) IL293758A (es)
JO (1) JOP20220140A1 (es)
MX (1) MX2022007227A (es)
NL (1) NL2024431B1 (es)
PH (1) PH12022551418A1 (es)
WO (1) WO2021118359A1 (es)
ZA (1) ZA202206837B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
NL2031091B1 (en) * 2022-02-28 2023-09-07 Sulfateq Bv Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
JP2025537481A (ja) * 2022-10-18 2025-11-18 イムヌジェネティクス アーゲー アルツハイマー型認知症に罹患している又はアルツハイマー型認知症を発症する危険性のある対象の特定

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339404A2 (en) * 2000-10-31 2003-09-03 Colgate-Palmolive Company Composition and method
HRP20150843T1 (hr) 2007-05-22 2015-09-11 Otsuka Pharmaceutical Co., Ltd. Lijek koji sadrži derivat karbostirila i donepezil za lijeäśenje alzheimerove bolesti
SI3456707T1 (sl) * 2007-11-06 2020-10-30 Ptc Therapeutics, Inc. Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni
ES2622190T5 (es) 2012-07-12 2020-04-23 Khondrion Ip B V Derivados de cromanilo para tratar una enfermedad mitocondrial
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
PT2994160T (pt) 2013-05-06 2019-08-07 Baxalta Inc Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada
WO2017060432A1 (en) 2015-10-08 2017-04-13 Khondrion Ip B.V. Novel compounds for treating mitochondrial disease
US11672787B2 (en) * 2017-11-22 2023-06-13 Khondrion Ip B.V. Compounds as mPGES-1 inhibitors

Also Published As

Publication number Publication date
IL293758A (en) 2022-08-01
NL2024431B1 (en) 2021-09-07
JP2023506480A (ja) 2023-02-16
ZA202206837B (en) 2023-11-29
AU2020400823A1 (en) 2022-06-23
EP4072550A1 (en) 2022-10-19
US20230052152A1 (en) 2023-02-16
BR112022011344A2 (pt) 2022-08-23
CA3164071A1 (en) 2021-06-17
WO2021118359A1 (en) 2021-06-17
GEAP202516676A (en) 2025-02-10
PH12022551418A1 (en) 2023-11-20
KR20220119032A (ko) 2022-08-26
JP7695246B2 (ja) 2025-06-18
JOP20220140A1 (ar) 2023-01-30
CL2022001520A1 (es) 2023-02-24

Similar Documents

Publication Publication Date Title
CL2022001520A1 (es) Compuestos para el tratamiento de la enfermedad de alzheimer
JOP20220247A1 (ar) مثبطات كرومينون تفارغية لفوسفوينوسيتيد 3 كيناز (pi3k) لعلاج أمراض مرتبطة بتعديل p13k
UY26782A1 (es) Derivados del benzotiazol
CY1121330T1 (el) Συνθεσεις που περιλαμβανουν αζελαστινη και μεθοδοι χρησης αυτων
CR20230517A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
GT200500098A (es) Nuevos compuestos
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
UY30025A1 (es) Derivados sustituidos de las 2-amino-5,6-dihidro pirimidin-4(3h)-onas y sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones.
DOP2002000422A (es) Agentes antibacterianos.
GB0112348D0 (en) Compounds
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
CL2023000800A1 (es) Compuestos de cromanol para el tratamiento de la insuficiencia cardíaca